08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Addex preclinical data

In nicotine-dependent mice, 1, 3 and 10 mg/kg oral ADX71441 administered 60 minutes prior to mecamylamine dose-dependently reversed somatic withdrawal signs. The 10 mg/kg dose of ADX71441 also reversed hyperalgesia. The data were generated as...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Addex autoimmune, neurology news

Addex said it plans to reduce the size of its operations in Geneva and its early stage discovery efforts to focus its resources on developing its pipeline for rare diseases. The company also said it...
03:00 , Feb 8, 2013 |  BC Extra  |  Company News

Addex refocusing pipeline, reducing Geneva operations

Addex Therapeutics Ltd. (SIX:ADXN) said it plans to reduce the size of its operations in Geneva and its early-stage discovery efforts to focus its resources on developing its pipeline for rare diseases. The company also...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

Addex preclinical data

In a rat model of CMT1A, 10 mg/kg oral ADX71441 given every other day for 5 weeks followed by once-daily 5 mg/kg ADX71441 for 4 weeks down regulated PMP22 mRNA, reduced the number of hypo-myelinated...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Addex preclinical data

In a validated mouse model of alcohol binge drinking, 3, 10 and 30 mg/kg oral ADX71441 dose-dependently reduced alcohol intake for the duration of the 4-hour study period vs. vehicle-treated controls. The 10 and 30...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

Addex preclinical data

In female guinea pigs with OAB, animals treated with 1 and 3 mg/kg IV ADX71441 had a "strong increase" in intercontraction interval, a measure of bladder muscle control, 15 minutes post-treatment vs. vehicle-treated controls. Additionally,...
08:00 , Dec 10, 2007 |  BioCentury  |  Product Development

Modifying Parkinson's

Most drugs for Parkinson's disease target dopamine, which provides short-term, palliative treatment but is accompanied by neurological side effects and eventually loses efficacy as patients develop tolerance. Addex Pharmaceuticals S.A. believes its allosteric modulators of...